Product Information
ZAVZPRET 10 MG NASAL SPRAY is a brand product labeled by Pfizer Inc., priced at $189.8006 per EA under NDC 00069350002. Its NADAC has been published 155 times since Oct 18, 2023.
FDA first approved this application on Mar 9, 2023.
Strength
10 mg/.1mL
Manufacturer
Pfizer Inc.NDC
00069350002
Classification
Brand
Dosage Form
SPRAY
Route
NASAL
Effective Date
9/23/2026
Active Ingredients
ZAVEGEPANT HYDROCHLORIDEApproval Type
New Drug (NDA)
FDA Application
NDA216386FDA Approved
3/9/2023
On Market Since
6/1/2023
Pharmacological Classes
Price Statistics
The NADAC for ZAVZPRET 10 MG NASAL SPRAY has been published 155 times since Oct 18, 2023, and over the history we have for it it has risen 7.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $189.8006 per EA |
|---|---|
| All-time high | $190.2039 (Jun 10, 2026) |
| All-time low | $175.9432 (Oct 18, 2023) |
| 52-week high | $190.2039 |
| 52-week low | $181.0969 |
| Median price | $181.1104 |
| Average price | $181.3971 |
| Largest weekly change | +5.0% (Dec 31, 2025) |
| Weeks tracked | 155 |
| Tracking since | Oct 18, 2023 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the zavegepant market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Pfizer Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
zavegepant market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Calcitonin Gene-related Peptide Receptor Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ZAVZPRET 10 MG NASAL SPRAY?
The current National Average Drug Acquisition Cost (NADAC) for ZAVZPRET 10 MG NASAL SPRAY, manufactured by Pfizer Inc., is $189.8006 per EA (NDC 00069350002), effective Sep 30, 2026.
How has the price of ZAVZPRET 10 MG NASAL SPRAY changed over time?
Over the history we have for it, the NADAC for ZAVZPRET 10 MG NASAL SPRAY has risen 7.9%. It has been tracked across 155 weekly CMS publications since Oct 18, 2023.
What are the highest and lowest recorded NADAC prices for ZAVZPRET 10 MG NASAL SPRAY?
Since Oct 18, 2023, the NADAC for ZAVZPRET 10 MG NASAL SPRAY has ranged from a low of $175.9432 (Oct 18, 2023) to a high of $190.2039 (Jun 10, 2026), with a median of $181.1104 per EA.
Are there cheaper alternatives to ZAVZPRET 10 MG NASAL SPRAY?
No other NADAC-published product currently shares the active ingredient and strength of ZAVZPRET 10 MG NASAL SPRAY in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ZAVZPRET 10 MG NASAL SPRAY?
ZAVZPRET 10 MG NASAL SPRAY (NDC 00069350002) is labeled by Pfizer Inc., and CMS classifies it as a brand product.